v3.25.4
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at July 25, 2025
Cash$389 
Acquired IPR&D(1)
608
Goodwill(2)
127
Other assets and liabilities, net39 
Acquisition date fair value of consideration transferred 1,163 
Less:
Cash acquired(389)
Fair value of CVR liability(177)
Fair value of equity interest in Verve held before the business combination(48)
Cash paid, net of cash acquired$549 
(1) Acquired IPR&D intangibles primarily relate to VERVE-102 (PCSK9 Editor).
(2) The goodwill recognized from this acquisition is primarily attributable to future unidentified projects and products and the assembled workforce for Verve, which is not deductible for tax purposes.
The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at December 27, 2023
Cash$303 
Acquired IPR&D196
Goodwill(1)
854
Other assets and liabilities, net(14)
Acquisition date fair value of consideration transferred 1,339 
Less:
Cash acquired(303)
Cash paid, net of cash acquired$1,036 
(1) The goodwill recognized from this acquisition is primarily attributable to the radiopharmaceutical discovery, development, and manufacturing capabilities and the assembled workforce for POINT, which is not deductible for tax purposes.
Schedule of Significant Acquired IPR&D Charges The following table summarizes our significant acquired IPR&D charges during 2025, 2024, and 2023.
Counterparty
Compound, Therapy, or Asset
Acquisition Month
Phase of Development(1)
Acquired IPR&D Charge
SiteOneSTC-004, Nav1.8 inhibitor for the treatment of painJuly
2025		Phase 1$494 
ScorpionSTX-478, PI3Kα inhibitor for the treatment of breast cancer and other advanced solid tumorsMarch 2025Phase 11,412 
MorphicMORF-057, inhibitor of α4β7 integrin for the treatment of inflammatory bowel diseaseAugust 2024Phase 22,549 
DICE Therapeutics, Inc. (DICE)
DC-806, an oral IL-17 inhibitor for the treatment of chronic diseases in immunology(2)
August 2023Phase 21,916 
Versanis Bio, Inc. (Versanis)Bimagrumab, a monoclonal antibody for the treatment of people living with obesity and obesity-related complicationsAugust 2023Phase 2604 
Emergence Therapeutics AG (Emergence)
ETx-22, a Nectin-4 antibody-drug conjugate for the treatment of urothelial cancerAugust 2023Pre-clinical407 
(1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.
(2) In 2024, we discontinued development of this molecule in favor of another molecule in development.